Journal
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
Volume 14, Issue -, Pages 201-209Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJGM.S292901
Keywords
ST elevation myocardial infarction; fibrinolysis therapy; percutaneous coronary intervention; coronavirus disease 2019; propensity score-matched analysis
Categories
Funding
- Chinese Cardiovascular Association V.G. Foundation [2017-CCA-VG-042]
- Beijing Key Clinical Department Project
Ask authors/readers for more resources
During the COVID-19 pandemic, fibrinolysis therapy combined with deferred PCI can reduce ischemia time and has a similar in-hospital adverse clinical outcome rate compared to patients who undergo primary PCI.
Introduction: The efficacy of fibrinolysis therapy with deferred percutaneous coronary angioplasty (FPCI) versus primary angioplasty (PPCI) during the coronavirus disease 2019 (COVID-19) pandemic is unclear when medical quarantine is needed. Patients and Methods: Acute ST segment elevation myocardial infarction (STEMI) patients underwent PPCI after finishing the screening protocol from January 23, 2020 to June 10, 2020 while FPCI was applied when COVID-19-confirmed cases reoccurred in Beijing near our hospital from June 11, 2020 to July 20, 2020. The door-to-balloon time (DTB) or door-to-needle time (DTN) as well as in-hospital adverse clinical outcomes were compared between the two groups. A propensity score-matched (PSM) analysis was performed to diminish the potential influence of confounding factors on the clinical outcomes. Results: A total of 126 STEMI patients underwent PPCI after finishing the screening protocol and 17 patients received FPCI before PSM. Patients who received FPCI were younger than patients who underwent PPCI (50.8 +/- 14.0 versus 64.1 +/- 14.2 years, p=0.001), and chronic kidney disease (CKD) was less common in FPCI patients than in patients who underwent PPCI (0% versus 24.6%, p=0.024). The DTN was significantly shorter than DTB (25.8 +/- 4.2 versus 61.1 +/- 10.7, p=0.000) before PSM. The DTN was significantly shorter than DTB (26.9 +/- 4.2 versus 64.9 +/- 23.6, p=0.000), however, the incidence rate of in-hospital ischemia and bleeding adverse clinical outcomes were comparable between the two groups after PSM. Conclusion: Fibrinolysis therapy combined with deferred PCI can reduce the ischemia time and has a similar in-hospital adverse clinical outcome rate compared with patients who underwent primary PCI during the COVID-19 pandemic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available